Business Context and Reporting Period
Company: Lexaria Bioscience Corp.
Filing Type: Form 8-K (Current Report)
Date of Report: May 18, 2017
Reporting Period: Events occurring on May 18 and May 19, 2017.
Key Financial Metrics
This filing reports a specific capital event rather than periodic financial performance. Key metrics include:
- Proceeds Received: US$970,230.05 from warrant exercises.
- Exercise Price: US$0.2273 per share.
- Shares Issued: 4,268,500 common shares.
- Total Outstanding Shares: 66,506,009 common shares following issuance.
- Transaction Costs: No commissions or placement fees were paid.
- Use of Proceeds: General corporate purposes.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity beyond the specific proceeds mentioned above.
Material Changes
The primary material change is the increase in outstanding common shares by 4,268,500 due to the exercise of warrants that otherwise would have expired on May 15, 2017. The exercise was conducted entirely by third parties who are neither officers nor directors of the Company.
Guidance, Outlook, and Risks
Management Commentary: The Company expressed gratitude to shareholders for their continued support. Additionally, the Company announced it will be featured on a special BTV episode exploring burgeoning cannabis enterprises.
Risks and Contingencies: The securities issued in this transaction were not registered under the United States Securities Act of 1933. Consequently, they may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Investor Verification Checklist
- Verify the total number of outstanding shares (66,506,009) against subsequent filings.
- Confirm the utilization of the US$970,230.05 proceeds for general corporate purposes in future financial statements.
- Review the referenced press releases (Exhibits 99.1 and 99.2) for details on the BTV feature and any additional strategic updates.
- Monitor the status of the unregistered securities to ensure compliance with US trading restrictions.